Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6409283 | 1.00 | SMN1; SMN2 (0.54) | SMN1; SMN2MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL4909312 | 0.95 | SMN1; SMN2 (0.55) | SMN1; SMN2MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL3019079 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL3019082 | 0.81 | SMN1; SMN2 (0.50) | SMN1; SMN2MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL10525108 | 0.79 | MAPT (0.53) | MAPTALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL8521479 | 0.79 | MAPT (0.53) | MAPTALDH1A1HTTKMT2AMEN1 | |
| SCHEMBL5695470 | 0.74 | MAPT (0.54) | SMN1; SMN2MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL14288490 | 0.73 | SMN1; SMN2 (0.45) | SMN1; SMN2MAPTALDH1A1HTTMAPK1 | |
| SCHEMBL12364014 | 0.73 | SMN1; SMN2 (0.68) | SMN1; SMN2MAPTALDH1A1NPSR1LMNA | |
| SCHEMBL2261888 | 0.73 | SMN1; SMN2 (0.68) | SMN1; SMN2MAPTALDH1A1NPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930124-B2 | Compounds derived from oxindoles and their therapeutic application in cancer treatment | AVENTIS PHARMA S. A. (FR) | 2005-08-16 | — | — | US | disclosed |
| US-20040082645-A1 | Compounds derived from oxindoles and their therapeutic application in cancer treatment | AVENTIS PHARMA S.A. (FR) | 2004-04-29 | — | — | US | disclosed |
| EP-1370555-A1 | COMPOUNDS DERIVED FROM OXINDOLES AND THE USE THEREOF IN CANCEROLOGY | Aventis Pharma S.A. (FR) | 2003-12-17 | — | — | EP | disclosed |
| EP-1366038-A1 | CDK-1 INHIBITOR OXINDOLES AND THE APPLICATION THEREOF IN THERAPEUTICS | Aventis Pharma S.A. (FR) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002072575-A1 | COMPOUNDS DERIVED FROM OXINDOLES AND THE USE THEREOF IN CANCEROLOGY | AVENTIS PHARMA S.A. (FR) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002068411-A1 | CDK-1 INHIBITOR OXINDOLES AND THE APPLICATION THEREOF IN THERAPEUTICS | AVENTIS PHARMA S.A. (FR) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082645-A1 | Compounds derived from oxindoles and their therapeutic application in cancer treatment | TUBB1, TUBB3, TUBA1C | SMN1; SMN2 2669/4885MAPT 241/4885ALDH1A1 1081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.